Maxim Group Cuts Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Price Target to $5.00

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX – Get Rating) had its target price trimmed by Maxim Group from $9.00 to $5.00 in a research note released on Wednesday, The Fly reports.

Separately, Cantor Fitzgerald assumed coverage on shares of Brooklyn ImmunoTherapeutics in a report on Wednesday, December 29th. They issued an overweight rating and a $9.00 price objective on the stock.

Shares of Brooklyn ImmunoTherapeutics stock opened at $1.24 on Wednesday. Brooklyn ImmunoTherapeutics has a twelve month low of $1.22 and a twelve month high of $80.67.

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX – Get Rating) last issued its quarterly earnings data on Friday, April 15th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03).

Institutional investors have recently modified their holdings of the company. Voya Investment Management LLC acquired a new stake in shares of Brooklyn ImmunoTherapeutics in the 3rd quarter valued at about $106,000. BlackRock Inc. raised its stake in shares of Brooklyn ImmunoTherapeutics by 27.3% in the 3rd quarter. BlackRock Inc. now owns 1,786,067 shares of the biotechnology company’s stock valued at $16,610,000 after purchasing an additional 383,176 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Brooklyn ImmunoTherapeutics in the 3rd quarter valued at about $453,000. Allegheny Financial Group LTD acquired a new stake in shares of Brooklyn ImmunoTherapeutics in the 3rd quarter valued at about $108,000. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Brooklyn ImmunoTherapeutics in the 3rd quarter valued at about $1,217,000.

About Brooklyn ImmunoTherapeutics (Get Rating)

Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

Read More